{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:26:16Z","timestamp":1782289576796,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ovarian cancer, particularly high-grade serous ovarian cancer (HGSOC), is the most lethal gynecological tumor, with most patients experiencing recurrence within 5 years. Long-term survival in HGSOC patients with advanced stages is exceedingly rare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>We report a case of advanced HGSOC with exceptional long-term recurrence-free survival following initial treatment. In June 2009, the patient underwent suboptimal cytoreductive surgery for stage IIIC ovarian cancer, including total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, appendectomy, and resection of mesenteric and peritoneal lesions. Postoperatively, residual lesions were observed in the mesenteries and para-aortic lymph nodes. Despite unfavorable prognostic factors (advanced stage, aggressive pathology, and incomplete resection), the patient showed remarkable chemosensitivity, remaining recurrence-free for 15 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The factors influencing long-term survival in HGSOC patients are not yet fully understood. We present this rare case to contribute data for further studies on long-term survival in advanced HGSOC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1468196","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:15:30Z","timestamp":1737954930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Disease-free survival of 15 years after primary surgery in a patient with advanced high-grade serous ovarian cancer: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yaoqi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangjing","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13048-022-01020-1","article-title":"Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review","volume":"15","author":"Nag","year":"2022","journal-title":"J Ovarian Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/diagnostics12123054","article-title":"Pathologic findings at risk reducing surgery in Brca and non-Brca mutation carriers: A single-center experience","volume":"12","author":"Cassani","year":"2022","journal-title":"Diagnost (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000114990.34357.b0","article-title":"Relapse after more than 20 years of follow-up for epithelial ovarian carcinoma","volume":"103","author":"Zylberberg","year":"2004","journal-title":"Obstet Gynecol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2021-0062","article-title":"Splenic and peritoneal metastases with para-aortic and Virchow lymph node metastases: late recurrence of ovarian cancer 30 years after initial treatment","volume":"4","author":"Takagi","year":"2021","journal-title":"JMA J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/030089161009600525","article-title":"Isolated splenic metastasis of ovarian cancer 20 years after operation: A case report and literature review","volume":"96","author":"Izuishi","year":"2010","journal-title":"Tumori"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/3938833","article-title":"Late recurrence of ovarian cancer after 18 years of disease-free survival: A case report and review of the literature","volume":"2024","author":"Suzuki","year":"2024","journal-title":"Case Rep Obstet Gynecol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S387120","article-title":"Germline Prdm1 variant Rs2185379 in long-term recurrence-free survivors of advanced ovarian cancer","volume":"15","author":"Mitamura","year":"2022","journal-title":"Pharmgenom Pers Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.03.010","article-title":"Characteristics of 10-year survivors of high-grade serous ovarian carcinoma","volume":"141","author":"Dao","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.10.032","article-title":"Who are the long-term survivors of high grade serous ovarian cancer","volume":"148","author":"Hoppenot","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13048-024-01482-5","article-title":"The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer","volume":"17","author":"Sarkar","year":"2024","journal-title":"J Ovarian Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21482","article-title":"The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer","volume":"101","author":"Weinberg","year":"2010","journal-title":"J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1007834","article-title":"Frailty and long-term survival of patients with ovarian cancer: A systematic review and meta-analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01230-9","article-title":"The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer","volume":"54","author":"Garsed","year":"2022","journal-title":"Nat Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (Ago-ovar) and the groupe D\u2019investigateurs nationaux pour les etudes des cancers de L\u2019ovaire (Gineco)","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.07.004","article-title":"What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (\u226510 years) survivors in Nrg\/Gog randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage Iii ovarian cancer","volume":"166","author":"Pitiyarachchi","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188503","article-title":"Roles of Ca125 in diagnosis, prediction, and oncogenesis of ovarian cancer","volume":"1875","author":"Zhang","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2005.00185.x","article-title":"Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors","volume":"15","author":"Kaern","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000721","article-title":"An integrative genomic analysis of formalin fixed paraffin-embedded archived serous ovarian carcinoma comparing long-term and short-term survivors","volume":"26","author":"Stalberg","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a Brca mutation (Solo1\/Gog 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the Paola-1\/Engot-Ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase iii trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (Athena-Mono\/Gog-3020\/Engot-Ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3614207","article-title":"A robust gene expression prognostic signature for overall survival in high-grade serous ovarian cancer","volume":"2019","author":"Zhao","year":"2019","journal-title":"J Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000672","article-title":"Combined immunoscore of Cd103 and Cd3 identifies long-term survivors in high-grade serous ovarian cancer","volume":"26","author":"Bosmuller","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.025","article-title":"Patient inflammatory status and Cd4+\/Cd8+ Intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer","volume":"151","author":"Pinto","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13116","article-title":"Immunotyping in tubo-ovarian high-grade serous carcinoma by Pd-L1 and Cd8+ T-lymphocytes predicts disease-free survival","volume":"129","author":"Bansal","year":"2021","journal-title":"APMIS"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100994","article-title":"Clinical and pathological significance of programmed cell death 1 (Pd-1)\/programmed cell death ligand 1 (Pd-L1) expression in high grade serous ovarian cancer","volume":"14","author":"Bas","year":"2021","journal-title":"Transl Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"Fda approval summary: mirvetuximab soravtansine-gynx for fralpha-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the javelin solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33155","article-title":"A healthy lifestyle and survival among women with ovarian cancer","volume":"147","author":"Hansen","year":"2020","journal-title":"Int J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-1327","article-title":"Tobacco smoking and survival following a diagnosis with ovarian cancer","volume":"31","author":"Wang","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/1055-9965.EPI-22-0877","article-title":"Lifetime exposure to cigarette smoke and risk of ovarian cancer by t-cell tumor immune infiltration","volume":"32","author":"Hathaway","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.06.485","article-title":"Physical activity and exercise in women with ovarian cancer: A systematic review","volume":"158","author":"Jones","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e2440279","DOI":"10.1001\/jamanetworkopen.2024.40279","article-title":"Diet and survival in black women with epithelial ovarian cancer","volume":"7","author":"Armidie","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B36","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1186\/s12967-024-05653-2","article-title":"Association between pre-diagnosis and post-diagnosis alternate Mediterranean diet and ovarian cancer survival: evidence from a prospective cohort study","volume":"22","author":"Chen","year":"2024","journal-title":"J Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1039\/d2fo01379g","article-title":"Pre-diagnosis fiber: carbohydrate intake ratio and mortality of ovarian cancer: results from a prospective cohort study","volume":"13","author":"Liu","year":"2022","journal-title":"Food Funct"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1039\/d1fo03825g","article-title":"Pre-diagnosis meat\u00a0intake and cooking method and ovarian cancer survival: results from the ovarian cancer follow-up study (Oops)","volume":"13","author":"Wei","year":"2022","journal-title":"Food Funct"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1039\/d4fo02417f","article-title":"Association between pre- and post-diagnosis healthy eating index 2020 and ovarian cancer survival: evidence from a prospective cohort study","volume":"15","author":"Liu","year":"2024","journal-title":"Food Funct"},{"key":"B40","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12905-021-01476-1","article-title":"Attributions of survival and methods of coping of long-term ovarian cancer survivors: A qualitative study","volume":"21","author":"Ketcher","year":"2021","journal-title":"BMC Womens Health"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.09.004","article-title":"Homologous recombination deficiency as an ovarian cancer biomarker in a real-world cohort: validation of decentralized genomic profiling","volume":"24","author":"Denkert","year":"2022","journal-title":"J Mol Diagn"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104469","article-title":"Impact of molecular testing on the surgical management of advanced epithelial ovarian\u00a0cancer","volume":"202","author":"Colombo","year":"2024","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1468196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:15:34Z","timestamp":1737954934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1468196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":42,"alternative-id":["10.3389\/fonc.2025.1468196"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1468196","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"article-number":"1468196"}}